1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 110,00 | 111,00 | 22:00 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Truist Securities startet Coverage für Abivax mit Kaufempfehlung und hohem Kursziel | 20 | Investing.com Deutsch | ||
| Mo | Truist Securities initiates coverage on Abivax stock with Buy rating | 13 | Investing.com | ||
| ABIVAX SA ADR Aktie jetzt für 0€ handeln | |||||
| Do | Abivax gains amid takeover speculation | 38 | Seeking Alpha | ||
| 04.11. | Citizens reiterates Market Outperform rating on Abivax stock at $114 target | 22 | Investing.com | ||
| 03.11. | Abivax reports improved quality of life in ulcerative colitis patients | 2 | Investing.com | ||
| 03.11. | Abivax meldet signifikant höhere Lebensqualität bei Colitis-ulcerosa-Patienten | 27 | Investing.com Deutsch | ||
| 03.11. | EQS-News: ABIVAX: Abivax Announces Patient-Reported Outcomes Data from the Phase 3 ABTECT Induction Trials of Obefazimod, Demonstrating Significant Improvements in Quality of Life for Patients with Ulcerative Colitis | 603 | EQS Group (EN) | EQS-News: ABIVAX
/ Key word(s): Study results
Abivax Announces Patient-Reported Outcomes Data from the Phase 3 ABTECT Induction Trials of Obefazimod, Demonstrating Significant... ► Artikel lesen | |
| 13.10. | Barclays initiates coverage on Abivax stock with Overweight rating | 74 | Investing.com | ||
| 10.10. | Guggenheim raises Abivax stock price target to $150 on obefazimod potential | 34 | Investing.com | ||
| 07.10. | Leerink Partners raises Abivax stock price target to $115 on IBD drug potential | 14 | Investing.com | ||
| 06.10. | Why Is Abivax Stock Trading Higher On Monday? | 11 | Benzinga.com | ||
| 06.10. | Top 1% Biotech Abivax Surges On 'Compelling' Results In A Highly Watched Disease | 13 | Investor's Business Daily | ||
| 06.10. | Abivax stock jumps after positive ulcerative colitis trial results | 9 | Investing.com | ||
| 06.10. | Abivax-Aktie legt nach positiven Studiendaten zu Colitis ulcerosa kräftig zu | 22 | Investing.com Deutsch | ||
| 06.10. | Abivax: Citizens bestätigt hohes Kursziel nach positiven Sicherheitsdaten | 39 | Investing.com Deutsch | ||
| 06.10. | Citizens reiterates Abivax stock rating with $114 price target | 3 | Investing.com | ||
| 06.10. | EQS-News: ABIVAX: Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies | 595 | EQS Group (EN) | EQS-News: ABIVAX
/ Key word(s): Conference/Study results
Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without... ► Artikel lesen | |
| 06.10. | Abivax Reports Positive 8-Week Results From Phase 3 Trials Of Obefazimod In Ulcerative Colitis | 21 | RTTNews | ||
| 05.10. | EQS-News: ABIVAX: Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data | 681 | EQS Group (EN) | EQS-News: ABIVAX
/ Key word(s): Conference/Study results
Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data
05.10.2025... ► Artikel lesen | |
| 01.10. | Citizens JMP Raises PT on ABIVAX Société Anonyme (ABVX) Stock | 17 | Insider Monkey |
1 2 3 4 5 Weiter >>
103 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| GERON | 0,980 | -2,22 % | Geron Corporation Announces Executive Leadership Transitions and Appointments | FOSTER CITY, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 1,808 | +0,78 % | Cardiff Oncology, Inc.: Cardiff Oncology Reports Third Quarter 2025 Results and Provides Business Update | - Announced positive data from the ongoing Phase 2 CRDF-004 trial evaluating onvansertib + standard of care for the treatment of first-line RAS-mutated metastatic colorectal cancer - - Expects to... ► Artikel lesen | |
| CYTOKINETICS | 58,00 | -0,85 % | Cytokinetics, Incorporated: Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) | ||
| CYTOMX THERAPEUTICS | 3,602 | +4,41 % | CytomX Therapeutics stock holds Overweight rating at Cantor Fitzgerald | ||
| CAPRICOR | 3,835 | -4,48 % | Capricor presents scalable framework for loading therapeutics into exosomes | ||
| SPERO THERAPEUTICS | 1,958 | -5,18 % | Spero Therapeutics, Inc.: Spero Therapeutics Announces Second Quarter 2025 Operating Results and Provides a Business Update | PIVOT-PO Phase 3 trial evaluating tebipenem Hbr in complicated urinary tract infection (cUTI) patients stopped early for efficacy following review by independent data monitoring committee (IDMC)Spero... ► Artikel lesen | |
| PTC THERAPEUTICS | 72,00 | +3,60 % | S&P Dow Jones Indices: Sandisk Set to Join S&P 500; Upwork, First Interstate BancSystem, PTC Therapeutics to Join S&P SmallCap 600 | NEW YORK, Nov. 24, 2025 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P SmallCap 600:
S&P SmallCap 600 constituent... ► Artikel lesen | |
| SYNDAX PHARMACEUTICALS | 16,600 | -3,49 % | Syndax skizziert auf Jefferies-Konferenz Wachstumsstrategie für hämatologische Therapien | ||
| ALIGOS THERAPEUTICS | 7,600 | -7,88 % | Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2025 Financial Results | SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, "Aligos"), a clinical stage biotechnology company focused on improving patient outcomes through... ► Artikel lesen | |
| DIANTHUS THERAPEUTICS | 36,400 | -4,21 % | Dianthus Therapeutics, Inc.: Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results | Claseprubart achieved statistically significant and clinically meaningful improvements in Myasthenia Gravis Activities of Daily Living (MG-ADL), Quantitative Myasthenia Gravis (QMG), and other efficacy... ► Artikel lesen | |
| XENCOR | 14,800 | +2,07 % | Xencor: Truist Securities startet Coverage mit Kaufempfehlung und sieht 83 % Kurspotenzial | ||
| KURA ONCOLOGY | 10,010 | -1,72 % | Kura Oncology: Strategische Einblicke zu Zypto/n auf der Jefferies Konferenz | ||
| UROGEN PHARMA | 23,600 | +0,85 % | UroGen Pharma Ltd.: UroGen Reports 77.8% Three-Month Complete Response Rate from Phase 3 UTOPIA Trial of UGN-103 and Receives FDA Agreement on NDA Submission Strategy in Recurrent LG-IR-NMIBC Based on UTOPIA Trial | PRINCETON, N.J., Nov. 06, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty... ► Artikel lesen | |
| QIAGEN | 41,790 | +1,79 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Die Profitabilität dürfte 2026 zumindest stabil bleiben... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 71,57 | +0,56 % | Novartis CEO paid top dollar for Avidity to become a 'leader in neuromuscular diseases' |
ABIVAX SA ADR gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 110,00 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ABIVAX SA ADR finden Sie auf Wallstreet Online.